A study of changes in tumor 18 F-FDG uptake from before to after 7 days of preoperative neoadjuvant EGFR-TKI treatment in 23 patients with NSCLC found that a ≥ −25% change in 18 F-FDG uptake 7 days after treatment could predict tumor remission (histopathological response) and increased tumor necrosis [14]. The gene discussed is EGFR; the disease is neoplasm.